Related references
Note: Only part of the references are listed.Impact of an Antimicrobial Stewardship Intervention on Shortening the Duration of Therapy for Community-Acquired Pneumonia
Edina Avdic et al.
CLINICAL INFECTIOUS DISEASES (2012)
Procalcitonin to Guide Initiation and Duration of Antibiotic Treatment in Acute Respiratory Infections: An Individual Patient Data Meta-Analysis
Philipp Schuetz et al.
CLINICAL INFECTIOUS DISEASES (2012)
Guidelines for the management of adult lower respiratory tract infections - Summary
M. Woodhead et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia
Wei Long et al.
RESPIROLOGY (2011)
Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections The ProHOSP Randomized Controlled Trial
Philipp Schuetz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009
W. S. Lim et al.
THORAX (2009)
Pyocalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations
Kenneth L. Becker et al.
CRITICAL CARE MEDICINE (2008)
Short- versus long-course antibacterial therapy for community-acquired pneumonia - A meta-analysis
George Dimopoulos et al.
DRUGS (2008)
Efficacy of short-course antibiotic regimens for community-acquired pneumonia: A meta-analysis
Jonathan Z. Li et al.
AMERICAN JOURNAL OF MEDICINE (2007)
Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study
Thomas M. File et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults
Lionel A. Mandell et al.
CLINICAL INFECTIOUS DISEASES (2007)
Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia a Randomized trial
Miriam Christ-Crain et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study
Rachida el Moussaoui et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults
MA Drehobl et al.
CHEST (2005)
Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults
J D'Ignazio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Gemifloxacin for the treatment of respiratory tract infections: In vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety
SM Bhavnani et al.
PHARMACOTHERAPY (2005)
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.
H Goossens et al.
LANCET (2005)
Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections:: cluster-randomised, single-blinded intervention trial
M Christ-Crain et al.
LANCET (2004)
Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community acquired pneumonia in adults
N Sopena et al.
JOURNAL OF CHEMOTHERAPY (2004)
Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin
P Léophonte et al.
RESPIRATORY MEDICINE (2004)
Epidemiology and etiology of community-acquired pneumonia
LA Mandell
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2004)
Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days
G Tellier et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
High-dose, short-course Levofloxacin for community-acquired pneumonia: A new treatment paradigm
LM Dunbar et al.
CLINICAL INFECTIOUS DISEASES (2003)
Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors.
P Léophonte et al.
MEDECINE ET MALADIES INFECTIEUSES (2002)
A European study on the relationship between antimicrobial use and antimicrobial resistance
SLAM Bronzwaer et al.
EMERGING INFECTIOUS DISEASES (2002)
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647)
C Muller-Serieys et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis
S Harbarth et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
Guidelines for the management of adults with community-acquired pneumonia - Diagnosis, assessment of severity, antimicrobial therapy, and prevention
MS Niederman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses
F Namour et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
